- $6.05bn
- $5.19bn
- $147.17m
Grail hits record high after Samsung backs rollout of cancer test in Asia
U.S. STOCKS ON THE MOVE-United Airlines, Fossil Group, T-Mobile
Grail jumps after Samsung backs rollout of cancer test in Asia
Samsung Elec, Samsung C&T to invest $110 million in healthcare company Grail
Brief: Samsung And GRAIL Announce Strategic Collaboration To Bring GRAIL's Galleri Multi-Cancer Early Detection Test To Asia
EU M&A rules morph from growth catalyst to weapon
U.S. RESEARCH ROUNDUP- Grail, Maplebear, Ocular Therapeutix
Brief: Grail Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Grail Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: GRAIL Announces Positive Top-Line Results From The Galleri PATHFINDER 2 Registrational Study
Cancer test maker Grail falls after Ningi Research's short position
Brief: Ningi Research Says Short Grail
U.S. STOCKS ON THE MOVE-Robinhood, Oklo, Chimera Investment
U.S. STOCKS ON THE MOVE-AbbVie, Millrose Properties, European Wax Center
Grail falls after Q1 revenue miss
Grail Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Grail Reports First Quarter 2025 Financial Results
Brief: Grail And Athenahealth Team Up To Offer Healthcare Providers Streamlined Ordering Of Grail's Galleri® Multi-Cancer Early Detection (Mced) Test
Grail Inc expected to post a loss of $7.05 a share - Earnings Preview